Marksons Pharma PAT at Rs 62.6 cr. for Q1FY22
The company has tied up with OrbiMed as a financial partner for global reach
The company has tied up with OrbiMed as a financial partner for global reach
The shareholders have also ratified the Board’s approval to allot 10 lakhs warrants to the Promoter, Managing Director and CEO, Mark Saldanha at the said price of Rs. 74 per warrant
The company's operating revenue for Q4 FY21 was Rs. 330.2 crore
Subscribe To Our Newsletter & Stay Updated